PH / H2O2 double-response hydrogel as well as preparation method and application thereof

By developing pH/H2O2 double-responsive hydrogel, functionalized glucan cross-linking using ε-polylysine derivatives and aldehyde groups, covalently loaded with CD73 inhibitors, the side effects and stability of existing cancer treatment methods have been solved. The sexual problems have achieved efficient tumor cell-induced death and activation of immune responses, significantly inhibiting tumor growth.

CN119015211AActive Publication Date: 2024-11-26ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411125743.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

Existing cancer treatment methods such as chemotherapy, radiotherapy and immunotherapy have side effects and therapeutic resistance problems, and the poor stability and low bioavailability of oncolytic peptides limit their large-scale application.

Method used

Develop a pH/H2O2 double-response injectable hydrogel, using ε-polylysine derivative as an anti-tumor active ingredient to cross-link functionalized glucans with aldehyde group, covalently loaded with CD73 small molecule inhibitor APCP, A potable hydrogel that can quickly form gels in weakly alkaline aqueous media is formed to induce tumor cell lysis death and reverse the immunosuppressive microenvironment.

Benefits of technology

This hydrogel can effectively induce tumor cell ICD, activate anti-tumor immune response, restore CD8+ T cells and NK cell functions, and jointly inhibit tumor growth. Its efficacy is better than that of the single drug oxaliplatin, and has good biosafety and Injectability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015211A_ABST
    Figure CN119015211A_ABST
Patent Text Reader

Abstract

The invention relates to pH / H2O2 dual-response drug-loaded hydrogel as well as a preparation method and application thereof. Epsilon-polylysine derivatives serving as anti-tumor active ingredients and oxidized dextran are subjected to Schiff base reaction and cross-linking to quickly form gel. Meanwhile, 2-formyl phenylboronic acid is used for carrying out covalent entrapment on a CD73 small-molecule inhibitor APCP. The epsilon-polylysine derivative has oncolytic activity, and can induce tumor cells to generate ICD and promote immune cell infiltration. The CD73 small-molecule inhibitor APCP can block an extracellular CD39-CD73-adenosine pathway and reduce the level of tumor tissue immunosuppressive metabolite adenosine, so that infiltrated immune cells are activated, and the anti-tumor function of the immune cells is recovered. The epsilon-polylysine derivative and APCP co-delivered hydrogel synergistically inhibits the tumor growth effect, and the curative effect of the epsilon-polylysine derivative and APCP co-delivered hydrogel is greater than that of a single drug and is superior to that of a positive control drug oxaliplatin (OXA). The pH / H2O2 double-response hydrogel is rapid in gelling, mild in reaction condition and good in biological safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical polymer materials, and in particular to a pH / H2O2 dual-responsive hydrogel and a preparation method and application thereof. Background Art

[0002] Cancer is a major and growing public health problem worldwide, resulting in high morbidity, mortality, and a severe economic burden. Currently, first-line cancer treatment options, including chemotherapy, radiotherapy, and immunotherapy, have improved the prognosis of cancer patients to a certain extent. However, these treatments still have some limitations, for example, chemotherapy and radiotherapy often lead to treatment resistance and serious side effects. In recent years, immunotherapy has been extensively and deeply studied, bringing new hope for tumor treatment, but the overall response rate of immunotherapy in clinical practice is low. Therefore, there is an urgent need to explore new cancer treatment strategies to improve the effectiveness of immunotherapy.

[0003] Oncolytic peptides contain a high proportion of hydrophobic amino acid residues and a certain number of positive charges. They can be adsorbed to the negatively charged tumor cell membrane surface through electrostatic action, inserted into the tumor cell membrane and cause the cell membrane integrity to be destroyed, ultimately causing tumor cell immunogenic death (ICD). The occurrence of ICD causes tumor cells to secrete adenosine triphosphate (ATP), recruit antigen-presenting cells (APCs) to the tumor immune microenvironment (TME) to initiate anti-tumor immune response. However, the ATP released into the extracellular space is rapidly metabolized into immunosuppressive adenosine through the CD39-CD73 pathway, resulting in impaired function of infiltrating CD8+T cells and natural killer (NK) cells. Using immunomodulators to block the extracellular CD39-CD73-adenosine pathway can amplify the immune response triggered by tumor ICD and inhibit tumor metastasis.

[0004] Although oncolytic peptides have been proven to kill tumor cells and induce immune responses, their large-scale in vivo application is still limited by factors such as poor stability, low bioavailability, cumbersome synthesis steps, and high prices, similar to most peptide drugs. In order to overcome the above-mentioned defects in the prior art, the present invention simulates oncolytic peptides to prepare an ε-polylysine derivative with anti-tumor activity. Summary of the invention

[0005] The present invention provides a pH / H2O2 dual-responsive injectable hydrogel, a preparation method and its application, in order to solve the above technical problems. The hydrogel uses ε-polylysine derivatives as anti-tumor active ingredients and gel skeletons, and reacts with aldehyde functionalized dextran through Schiff base reaction to generate imine dynamic bond cross-linking to quickly gelate, while introducing 2-formylphenylboronic acid to form boronate bonds to covalently encapsulate CD73 small molecule inhibitors: one of APCP, AB680, and PSB-12379, to reverse the immunosuppressive microenvironment of tumor tissues and synergistically inhibit tumor growth.

[0006] The present invention is achieved through the following technical solutions:

[0007] An injectable anti-tumor hydrogel, the structural composition of which is: Ax-ran-By-ran-Ca-ran-Lb-D.

[0008] Wherein Ax is shown in Formula A; By is shown in Formula B; Ca is shown in Formula C; Lb is shown in Formula L; and D is shown in Formula III:

[0009]

[0010] Among them, 1≤x≤15;

[0011]

[0012] Among them, 5≤y≤30;

[0013]

[0014] Among them, 2.5≤a≤6.5;

[0015]

[0016] Among them, 20≤b≤60;

[0017]

[0018] Wherein, 10≤n≤120, m is the structural unit modified by oxidation in n, wherein the percentage of the oxidized structural unit is 40%≤m / n≤85%.

[0019] The amino group of formula L reacts with the aldehyde group of formula D, and the molar ratio of the amino group of formula L to the aldehyde group of formula D is 1:1.5-3.0.

[0020] The overall structure of the hydrogel is shown in Formula I, and the ε-polylysine derivative of the structure described in Formula II is used as the anti-tumor active ingredient and the gel skeleton, and is mixed with the aldehyde functionalized dextran shown in Formula III in a weakly alkaline aqueous medium to obtain the hydrogel;

[0021]

[0022] Among them, 1≤x≤15, 5≤y≤30, 2.5≤a≤6.5, 20≤b≤60.

[0023]

[0024] Among them, 12≤z≤18, 1≤x≤15, 5≤y≤30.

[0025] Furthermore, the aldehyde functionalized dextran has a structure shown in Formula III:

[0026]

[0027] Wherein, 10≤n≤120, m is the structural unit modified by oxidation in n, wherein the percentage of the oxidized structural unit is 40%≤m / n≤85%.

[0028] Further, the APCP has a structure shown in Formula IV:

[0029]

[0030] Furthermore, the AB680 has a structure shown in Formula V:

[0031]

[0032] Furthermore, the PSB-12379 has a structure shown in Formula VI:

[0033]

[0034] On the other hand, the present invention also provides a method for preparing the above-mentioned pH / H2O2 dual-responsive injectable hydrogel, which specifically comprises the following steps:

[0035] First, ε-polylysine derivatives, 2-formylphenylboronic acid and APCP are dissolved in a weakly alkaline aqueous medium, and then an aldehyde-functionalized dextran solution is added and mixed to obtain a drug-loaded hydrogel material.

[0036] Furthermore, the mass ratio of the ε-polylysine derivative to the aldehyde-functionalized dextran is 1:g-1.32; the molar ratio of the amino group in the ε-polylysine derivative to the aldehyde group in the aldehyde-functionalized dextran is 1:1.5-3; and the mass ratio of the ε-polylysine derivative to APCP is 1:0.15-0.35.

[0037] Furthermore, the solvent is weak alkaline water, physiological saline or buffer solution; wherein the pH of the weak alkaline water is 7.4-8.5; the mass-volume concentration of the aldehyde functionalized dextran is 7%-20%; the mass-volume concentration of the ε-polylysine derivative is 7%-20%; and the mixing temperature is 15-37°C.

[0038] Furthermore, the aldehyde-functionalized dextran is obtained by oxidation reaction of natural polysaccharide dextran with periodate in a solvent under light-proof and room temperature conditions to obtain a polymer shown in formula II; wherein the solvent is water and the periodate is a sodium salt or a potassium salt.

[0039] In a third aspect, the present invention also provides the application of the pH / H2O2 dual-responsive injectable hydrogel, which can induce tumor cell lysis and death and trigger ICD, and can also reverse the immunosuppressive microenvironment of tumor tissue, activate anti-tumor immune response and synergistically inhibit tumor growth. The pH / H2O2 dual-responsive injectable hydrogel has at least one of the following uses:

[0040] (1) Inducing ICD in tumors;

[0041] (2) Promote the maturation of dendritic cells;

[0042] (3) increase T cell infiltration in the tumor microenvironment;

[0043] (4) Upregulation of NK cell proportion;

[0044] (5) Reversing the tumor immunosuppressive microenvironment.

[0045] The benefits of the present invention are:

[0046] 1) The present invention provides a pH / H2O2 dual-responsive injectable hydrogel, a preparation method and its application, wherein the hydrogel is cross-linked with oxidized dextran through Schiff base reaction to form a gel quickly. At the same time, 2-formylphenylboronic acid is used to covalently encapsulate the CD73 small molecule inhibitor APCP. The ε-polylysine derivative has oncolytic activity, can induce ICD in tumor cells and promote immune cell infiltration. The CD73 small molecule inhibitor APCP can block the extracellular CD39-CD73-adenosine pathway, reduce the level of adenosine, an immunosuppressive metabolite in tumor tissue, thereby activating infiltrating immune cells and restoring their anti-tumor function. The hydrogel co-delivered with ε-polylysine derivatives and APCP synergistically inhibits tumor growth, and its therapeutic effect is greater than the therapeutic effect of a single drug, and is better than the positive control drug oxaliplatin (OXA).

[0047] 2) The pH / H2O2 dual-responsive injectable hydrogel gels quickly, has mild reaction conditions, and has good biosafety. The hydrogel can allow small molecule APCP drugs to reside in the tumor site for a long time in the body, play a reservoir effect, and enhance the tumor treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 These are two state diagrams of the drug-loaded hydrogel (OP@APCP gel) prepared in Example 1 of the present invention before and after gelation.

[0049] Figure 2 This is a characterization diagram of the injectability of drug-loaded hydrogel (OP@APCP gel).

[0050] Figure 3 The microscopic morphology of blank hydrogel (OP gel) and drug-loaded hydrogel (OP@APCP gel) was observed by scanning electron microscopy.

[0051] Figure 4 The viscosity of the hydrogel changes with shear rate.

[0052] Figure 5 The modulus of the hydrogel changes with frequency.

[0053] Figure 6 The modulus of the hydrogel changes with time.

[0054] Figure 7 The modulus of blank gel and drug-loaded gel changes with time.

[0055] Figure 8 Scanning electron microscopy results showing hydrogel destroying tumor cell membranes.

[0056] Fig. 9 This is a diagram showing the result of hydrogel inducing the release of ATP from tumor cells to the extracellular space.

[0057] Fig.10 This is an analysis diagram of the results of drug-loaded hydrogel inhibiting the conversion of ATP to adenosine (ADO).

[0058] Fig.11 The figure is a statistical chart of the body weight of mice in different drug-dosing groups.

[0059] Fig.12 This is a statistical diagram of tumor volume in a mouse breast cancer model under different treatment conditions.

[0060] Fig.13 The figure is a statistical chart of tumor mass of mice in different drug-dosing groups.

[0061] Fig.14 This is a flow cytometric image of DC cells (CD80+CD86+) in the tumor microenvironment.

[0062] Fig.15 for Fig.11 Statistical analysis chart of .

[0063] Fig.16 Flow cytometric images of NK cells in the tumor microenvironment.

[0064] Fig.17 for Fig.13 Statistical analysis chart of . DETAILED DESCRIPTION

[0065] Comparative Example 1

[0066] Preparation of blank hydrogel (OP gel):

[0067] Weigh 10 mg of ε-polylysine derivative (z=15, x=4.5, y=10), 0.67 mg of 2-formylphenylboronic acid and 6.58 mg of oxidized dextran (m=120, n=93). Dissolve the ε-polylysine derivative and 2-formylphenylboronic acid in PBS (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. The ε-polylysine derivative solution and the oxidized dextran solution were mixed in different ratios (10% (W / V) solution was mixed in a ratio of 1:1.2 or 1:0.87, and the 15% (W / V) solution was mixed in a ratio of 1:0.84 or 1:0.79 or 1:0.58), and the oxidized dextran solution was added dropwise to the mixed solution containing the ε-polylysine derivative, vortexed for 10 minutes, and mixed evenly to obtain OP gel.

[0068] Example 1

[0069] Preparation of drug-loaded hydrogel (OP@APCP gel):

[0070] Weigh a certain amount of 10 mg of ε-polylysine derivative (z=15, x=4.5, y=10), 0.67 mg of 2-formylphenylboronic acid, 1.66 mg of APCP and 6.58 mg of oxidized dextran (m=120, n=93). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. The ε-polylysine derivative solution and the oxidized dextran solution were mixed in different ratios (10% (W / V) solution was mixed in a ratio of 1:1.2 or 1:0.87, and the 15% (W / V) solution was mixed in a ratio of 1:0.84 or 1:0.79 or 1:0.58. The oxidized dextran solution was added dropwise to the mixed solution containing the ε-polylysine derivative, vortexed on a vortexer for 10 minutes, and mixed evenly to obtain OP@APCP gel (x=4.5y=10a=3b=21) in which the amino group of the ε-polylysine derivative and the aldehyde group of the dextran functionalized with aldehyde groups had a ratio of N:C=1:1.5; 1:2; 1:3.

[0071] Example 2

[0072] Weigh 10 mg of ε-polylysine derivative (z=15x=4.5y=10), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=93) (8.77 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix and react evenly to obtain OP@APCP gel (x=4.5y=10a=3b=36).

[0073] Example 3

[0074] Weigh 10 mg of ε-polylysine derivative (z=15x=4.5y=10), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=93) (13.15 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix well and react to obtain OP@APCP gel (x=4.5y=10a=3b=54).

[0075] Example 4

[0076] Weigh 10 mg of ε-polylysine derivative (z=15x=4.5y=10), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=80) (7.98 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix and react evenly to obtain OP@APCP gel (x=4.5y=10a=3b=28).

[0077] Example 5

[0078] Weigh 10 mg of ε-polylysine derivative (z=15x=4.5y=10), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=80) (10.65 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix and react evenly to obtain OP@APCP gel (x=4.5y=10a=3b=37.5).

[0079] Example 6

[0080] Weigh 10 mg of ε-polylysine derivative (z=17x=4.5y=8), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=93) (7.55 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix well and react to obtain OP@APCP gel (x=4.5y=8a=3b=23).

[0081] Example 7

[0082] Weigh 10 mg of ε-polylysine derivative (z=17x=4.5y=8), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=93) (10.07 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix and react evenly to obtain OP@APCP gel (x=4.5y=8a=3b=30).

[0083] Example 8

[0084] Weigh 10 mg of ε-polylysine derivative (z=17x=4.5y=8), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=93) (15.11 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix and react evenly to obtain OP@APCP gel (x=4.5y=8a=3b=46).

[0085] Example 9

[0086] Weigh 10 mg of ε-polylysine derivative (z=17x=4.5y=8), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=80) (9.17 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix well and react to obtain OP@APCP gel (x=4.5y=8a=3b=24).

[0087] Example 10

[0088] Weigh 10 mg of ε-polylysine derivative (z=17x=4.5y=8), 2-formylphenylboronic acid (0.67 mg), APCP (1.66 mg) and oxidized dextran (m=120n=80) (12.22 mg). Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and APCP in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare 10% (W / V) and 15% (W / V) solutions. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix well and react to obtain OP@APCP gel (x=4.5y=8a=3b=32).

[0089] Embodiment 11

[0090] Preparation of drug-loaded hydrogel (OP@AB680 gel):

[0091] Weigh 10 mg of ε-polylysine derivative, 0.67 mg of 2-formylphenylboronic acid, 2.35 mg of AB680 and 6.58 mg of oxidized dextran. Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and AB680 in PBS buffer (pH 7.4) to prepare a 10% (W / V) solution. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare a 10% (W / V) solution. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, and mix well to obtain OP@. AB680 gel.

[0092] Example 12

[0093] Preparation of drug-loaded hydrogel (OP@PSB-12379gel):

[0094] Weigh 10 mg of ε-polylysine derivative, 0.67 mg of 2-formylphenylboronic acid, 2.61 mg of PSB-12379 and 6.58 mg of oxidized dextran. Dissolve the ε-polylysine derivative, 2-formylphenylboronic acid and PSB-12379 in PBS buffer (pH 7.4) to prepare a 10% (W / V) solution. Dissolve the oxidized dextran in PBS buffer (pH 7.4) to prepare a 10% (W / V) solution. Add the oxidized dextran solution dropwise to the mixed solution containing the ε-polylysine derivative, vortex for 10 minutes, mix well and react to obtain OP@PSB-12379gel.

[0095] Experimental Example 1

[0096] Comparative Example 1 and Example 1 prepared hydrogel before and after gelation at room temperature Figure 1 As shown in Figure 2, the prepared hydrogel has lost its fluidity and reached a macroscopic gel state. The injectability characterization results are shown in Figure 2. Figure 2 As shown, it is verified that the hydrogel does have good injectable properties. The prepared OP gel and OP@APCP gel were observed by scanning electron microscopy. Specifically, the two hydrogel samples were frozen and fixed, frozen and fractured, and the brittle fracture surface was sprayed with gold, and the microscopic morphology was observed by scanning electron microscopy. Figure 3 The results show that the three-dimensional network structure inside the hydrogel provides a basis for loading a variety of drugs. Figure 3 The hydrogel voids became compact, but its internal microstructure remained basically unchanged, indicating that drug loading had no significant effect on the formation of the hydrogel skeleton.

[0097] Experimental Example 2

[0098] The rheological properties of the hydrogels of OP gel and OP@APCP gel in Comparative Example 1 and Example 1 were investigated: a rheometer was used to study the rheological behavior of the hydrogels at different shear rates and frequencies and the change of the modulus over time.

[0099] The data were collected at a constant temperature and a strain amplitude of 1% to observe the change in viscosity with shear rate. Figure 4 shown.

[0100] The data were collected at a constant temperature and a strain amplitude of 1%, and the storage modulus (G') and loss modulus (G") were observed to vary with frequency. Figure 5 shown.

[0101] The data were collected at a constant temperature and a strain amplitude of 1%, and the storage modulus (G') and loss modulus (G") were observed over time. Figure 6 , as shown in 7

[0102] Rheological analysis of the hydrogel was performed. By testing the effect of shear rate on the viscosity of the hydrogel, we found that as the shear rate increased, the viscosity of the hydrogel gradually decreased, which showed the shear thinning property of the hydrogel. At 1% strain, the storage modulus of the gel material was always higher than the loss modulus, proving that the hydrogel was successfully prepared and maintained a high elastic state.

[0103] Experimental Example 3

[0104] OP gel has a destructive effect on the cell membrane of 4T1. 4 4T1 cells were inoculated in 12-well plates and incubated for 24 hours. 4T1 cells were incubated with OP gel under different pH conditions (pH7.4, pH6.5). At the same time, the blank control group was incubated with an equal volume of culture medium. The culture was terminated after incubation for 1 hour, 3 hours and 5 hours, respectively. After fixation, dehydration and drying, the slides were placed under a scanning electron microscope to observe the cell membrane damage. Figure 8 As shown, the Schiff base bonds of the hydrogel break faster under acidic conditions, resulting in the rapid release of ε-polylysine derivatives from the hydrogel to exert anti-tumor effects.

[0105] Experimental Example 4

[0106] The ability of drug-loaded hydrogels to induce cell membrane lysis and release ATP into the extracellular space was evaluated. 5 4T1 cells were seeded in 6-well plates and incubated with free APCP, OP@APCP gel, and PBS for 12 h. Subsequently, ATP production was characterized by an ATP assay kit. Fig. 9 As shown, OP@APCP gel induced a large amount of ATP generation.

[0107] Experimental Example 5

[0108] Evaluation of the effect of drug-loaded hydrogels in inhibiting the conversion of ATP to adenosine (ADO). The ε-polylysine derivatives in the hydrogels induce a large amount of ATP release after acting on tumor cells, and ATP is metabolized into immunosuppressive ADO through the CD39-CD73 pathway. APCP, a small molecule inhibitor of CD73 in drug-loaded hydrogels, can inhibit the conversion of ATP to ADO, thereby reversing the immunosuppressive microenvironment. Fig.10 As shown, a large amount of ADO was produced in the cell supernatant after OP gel treatment, while ADO was reduced to normal levels after OP@APCP gel treatment.

[0109] Experimental Example 6

[0110] In vivo anti-tumor experiment. Construction of 4T1 breast cancer model: Digest and collect 4T1 cells in the logarithmic growth phase and in good growth state, count and adjust the cell concentration to 3×10 6 100 μL of cell suspension was taken and injected into the mouse subcutaneously to establish a mouse breast cancer model. When the tumor volume grew to about 60-100 mm 3 The mice were randomly divided into 4 groups, each with 5 mice (n=5). The groups were as follows: PBS, OXA (oxaliplatin), OP gel, and OP@APCP gel.

[0111] The drug was administered by intratumoral injection. Starting from day 0, the tumor volume of the mice was measured with a vernier caliper every two days and the weight of the mice was recorded. The treatment was terminated on day 11, and the mice were killed. The tumors of the mice in each group were collected and weighed.

[0112] The weight changes of mice in each group were compared with Fig.11 As shown, there was no significant change in the weight of mice, indicating that the hydrogel had good biosafety.

[0113] The tumor volume of mice was measured every two days, and the tumor volume growth curve of each group of mice was referenced Fig.12 As shown, compared with the PBS group, the other groups showed different degrees of inhibitory effects.

[0114] OXA and OP gel showed moderate inhibitory effects on tumor growth, with no significant difference between the two groups. OP@APCPgel showed better in vivo antitumor effects than the positive drug (OXA).

[0115] After treatment, the tumor weight was measured. Fig.13 As shown in the figure, the OP@APCP gel treatment group had the lightest tumor tissue weight and the best treatment effect.

[0116] Experimental Example 7

[0117] After 3 days of treatment, tumor tissues were removed from mice, cut into small pieces, and incubated with 1640 containing collagenase IV at 37°C for 2 hours. After enzymatic hydrolysis, single cell suspension was obtained by filtration through a filter. Next, all dendritic cells (DCs) were stained with antibodies against anti-CD11c-APC, anti-CD80-FITC, and anti-CD86-PE according to the instructions for use, and the proportion of mature DCs was detected by flow cytometry. The results are shown in Figure 2. Fig.14 and 15As shown in the figure, the mature DC rate in PBS-treated mice was about 7.96%. After OXA and OP gel treatment, the proportion of mature DC increased to 17.3% and 18.5%, respectively, which is related to the ICD effect caused by anti-tumor drugs. The content of mature DCs in mice treated with OP@APCP gel was the highest, at 26.7%, which was 1.5 times that of the positive control group (OXA), indicating that the OP@APCP gel group had the best effect in activating anti-tumor immune responses, which may be due to APCP reducing the level of adenosine in the tumor, relieving the inhibition of DC, and further increasing the content of mature DC.

[0118] In addition, adenosine can also cause damage to the function of natural killer (NK) cells, which is not conducive to the immune function. According to the instructions, NK was stained with anti-NK1.1-Blue antibody, and the proportion of NK was detected by flow cytometry. The results are as follows Fig.16 and 17 As shown in the figure, after treatment with OP@APCP gel, the activation ratio of NK cells was significantly increased compared with that in the OP gel group, which indicated that the inhibitory effect of adenosine on NK cells was reversed.

Claims

1. A pH / H2O2 dual-responsive hydrogel, characterized in that: The preparation method is as follows: The ε-polylysine derivative and 2-formylphenylboronic acid are dissolved in a solvent, and the aldehyde functionalized dextran is added and mixed for reaction to obtain a hydrogel.

2. The pH / H2O2 dual-responsive hydrogel according to claim 1, characterized in that: The ε-polylysine derivative has a structure shown in Formula I: Among them, 12≤z≤18, 1≤x≤15, 5≤y≤30.

3. The pH / H2O2 dual-responsive hydrogel according to claim 1 or 2, characterized in that: The aldehyde functionalized dextran has a structure shown in Formula II: Among them, 10≤n≤120, 40%≤m / n≤85%.

4. The pH / H2O2 dual-responsive hydrogel according to claim 1 or 2, characterized in that: The molar ratio of the amino group in the ε-polylysine derivative to the aldehyde group in the aldehyde functionalized dextran is 1:1.5-3.

0.

5. The pH / H2O2 dual-responsive hydrogel according to claim 1 or 2, characterized in that: The mass ratio of the ε-polylysine derivative to the aldehyde functionalized dextran is 1:0.65-1.32; the mass ratio of the ε-polylysine derivative to 2-formylphenylboronic acid is 1:0.06-0.

1.

6. The pH / H2O2 dual-responsive hydrogel according to claim 1 or 2, characterized in that: The solvent is water, physiological saline or buffer solution with a pH of 7.4-8.

5.

7. A preparation comprising the pH / H2O2 dual-responsive hydrogel according to any one of claims 1 to 6, characterized in that: The preparation also contains an anti-tumor component, and the anti-tumor active component is selected from any one of APCP, AB680 or PSB-12379.

8. A method for preparing the hydrogel preparation according to claim 7, characterized in that: The following steps are involved: The ε-polylysine derivative, 2-formylphenylboronic acid and any one anti-tumor active component selected from APCP, AB680 or PSB-12379 are dissolved in a solvent, and aldehyde functionalized dextran is added for mixed reaction to obtain a drug-loaded hydrogel.

9. The method for preparing a preparation according to claim 8, characterized in that: The mass ratio of the ε-polylysine derivative to APCP is 1:0.15-0.

35.

10. Use of the pH / H2O2 dual-responsive hydrogel according to any one of claims 1 to 6 or the hydrogel preparation according to claim 7 in the preparation of anti-tumor drugs.

11. The use according to claim 10, characterized in that The tumor is a breast cancer tumor.

Citation Information

Patent Citations

  • Degradable healing-promoting medical adhesive and preparation method thereof

    CN116549712A

  • Double-response hydrogel with three-dimensional topological structure as well as synthesis method and application of double-response hydrogel

    CN116790043A

  • Bi-component aldehyde dextran hydrogel and preparation method thereof

    CN117777495A

  • Epsilon-polylysine derivative as well as preparation method and application thereof

    CN117866191A

  • PH (Potential of Hydrogen) and ROS (Reactive Oxygen Species) sensitive antibacterial injectable hydrogel

    CN118206848A